Robbe Heestermans Highlights cfDNA as a Tool for Liquid Biopsy in Multiple Myeloma
Robbe Heestermans, PhD Fellow Strategic Basic Research at Research Foundation Flanders FWO, shared a post on LinkedIn about a paper published on ASH Publications:
“Dear network,
I am happy to share with you the results of our latest study ‘Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma’, which has been published in Blood Advances, an official journal of the American Society of Hematology.
In this study, we demonstrate the value of cell free DNA (cfDNA) as a non-invasive tool for DNA methylation profiling in multiple myeloma (MM). This is the first comprehensive study investigating and comparing the DNA methylation profiles obtained with liquid biopsies in MM, opening the door for less invasive, multi-omics diagnostic strategies in clinical care.
Many thanks to my supervisors Ivan Van Riet, Elke De Bruyne, Rik Schots and Marleen Bakkus for their support as well as to the other co-authors Catharina Olsen, Shervine Ameli, Jana Succari, Toon Janssen, Wouter De Brouwer, Ann De Becker and Isabelle Vande Broek.
This study was supported by the Research Foundation Flanders – FWO, Kom op tegen Kanker, the King Baudouin Foundation, the VUB Strategic Research Program, and the UZ Brussel Foundation.
Check it out here.”
Title: Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma
Authors: Robbe Heestermans, Catharina Olsen, Shervine Ameli, Jana Succari, Toon Janssen, Wouter De Brouwer, Ann De Becker, Isabelle Vande Broek, Marleen Bakkus, Rik Schots, Elke De Bruyne, Ivan Van Riet
More posts featuring multiple myeloma on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023